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Nitric oxide is generated from L-arginine by nitric oxide
synthase (NOS), an enzyme that exists in several isoforms.
Some studies found that a polymorphism (G894T) in the
endothelial NOS gene was associated with decreased nitric
oxide bioactivity and vascular complications. However, it is
not known whether the enzyme had a reduced activity. Here
we measured the effect of an infusion of L-arginine on renal
hemodynamic function in subjects segregated by the
presence or absence of the T allele. If this polymorphism
represented a functional variant, subjects with the GT/TT
form should exhibit a blunted renal hemodynamic response
to L-arginine compared to those with a GG allele. All subjects
were given a diet controlled for sodium and protein intake.
GG subjects had lower mean arterial pressure and an
augmented glomerular filtration rate at baseline. In response
to a graded L-arginine infusion, this group had significant
changes in effective renal plasma flow, glomerular filtration
rate, filtration fraction, renal vascular resistance, and renal
blood flow. The renal response to L-arginine in GT/TT subjects
was blunted. Circulating cGMP levels and endothelial NOS
mRNA expression, measured in skin biopsies by real-time
PCR, did not differ between the groups. Our study shows that
the G894T allele of endothelial NOS is associated with a
blunted response to L-arginine, suggesting this
polymorphism may be a functional variant in humans.
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Several polymorphisms of the endothelial nitric oxide
synthase (eNOS) gene have been identified, including the
G894T polymorphism.1–3 Previous studies have suggested
that this missense mutation, which leads to a substitution of
aspartate to glutamate in the eNOS protein at position 894,
renders this molecular variant more susceptible to proteolytic
cleavage, reduced enzymatic activity, and lower basal
endothelial nitric oxide (NO) production.2 Impaired eNOS
activity may diminish arteriolar vasodilatation, thereby
blunting protective vascular effects that have been attributed
to NO.4–6 From a clinical perspective, decreased NO
bioactivity may predispose patients to the development of
hypertension, cardiovascular end-organ damage and nephro-
pathy related to diabetes mellitus.1,2,7–10
The G894T eNOS gene polymorphism has been associated
with impaired endothelial dependent vasodilatation, which
may either be on the basis of augmented vasoconstrictor
activity or a reduction in the generation of vasodilators, such
as NO.4–6 For example, we have shown in a previous study
that the presence of the T allele is associated with an
exaggerated renal vasoconstrictive response to a graded
infusion of angiotensin II (Ang II).11 In spite of these
studies, the functional status of this polymorphism remains
controversial, because other studies have failed to detect
functional differences between those with and without the T
allele.5 Whether the G894T polymorphism influences renal
hemodynamic functional responses to eNOS enzymatic
activation in normal humans is not known.
Accordingly, we examined the effect of a graded L-arginine
infusion on renal hemodynamic function in two groups: the
first group included subjects who were either homozygous or
heterozygous for the T allele (GT/TT subjects), and the
second group consisted of those without the T allele (GG
subjects). Our rationale reflected the possibility that the
pattern of renal hemodynamic responsiveness to L-arginine,
the substrate for eNOS, might clarify whether the poly-
morphism is functional. We also measured baseline eNOS
mRNA expression in skin biopsy specimens, hypothesizing
that the presence of the T allele would predict a blunted renal
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hemodynamic response to L-arginine, in spite of similar
eNOS expression.
RESULTS
Baseline characteristics
Baseline characteristics were similar in the GG (n¼ 16) and
GT/TT (n¼ 14) groups (Table 1), except that the GT/TT
group was older than the GG group. At baseline, the SBP was
lower and the glomerular filtration rate (GFR) was higher in
GG vs GT/TT subjects (Po0.05; Table 2). The GG group
contained 6 men and 10 women and the GT/TT group 10
men and 5 women. These differences were not statistically
significant.
Group differences in renal hemodynamic function
Although the systemic impact of L-arginine was similar in the
two groups (Table 2), the increased SBP in GT/TT subjects
was sustained at the 100 and 250 mg/kg doses of L-arginine.
In GG genotype subjects, the L-arginine infusion was
associated with increases in GFR, estimated renal plasma
flow (ERPF), and renal blood flow (RBF), and a decline in
renal vascular resistance (RVR; Table 2; Figures 1 and 2). GFR
values were also significantly higher in GG subjects at the
100, 250, and 500 mg/kg doses of L-arginine (Table 2). In
contrast, in the GT/TT group, the renal hemodynamic
changes were limited to a rise in ERPF at the highest infusion
rate, and a decline in RVR. The between-group rise in ERPF
in response to L-arginine was augmented in GG subjects at
the 100, 250, and 500 mg/kg doses (Po0.05 for each of the
two infusion rates). There was no significant interaction
between renal hemodynamic responsiveness and gender
(P40.05 for gender).
Circulating RAS components, cGMP, and skin eNOS
expression in GG vs GT/TT polymorphism subjects
The impact of the L-arginine infusions on circulating cyclic
30,50-guanosine monophosphate (cGMP) and RAS mediators
was similar (Table 3). Skin eNOS expression was similar in
the GG compared to the GT/TT group (Figure 3). There was
no significant interaction between gender and circulating
RAS components, cGMP, or eNOS expression (P40.05).
DISCUSSION
Several previous studies have suggested that the G to T
substitution at position 894 of the eNOS gene is associated
with dose-dependent reductions in enzymatic activity and
lower basal endothelial NO production,7–9 however this
Table 1 | Baseline characteristics (mean±s.e.m.)
Parameter GG group GG/TT group
n=16 n=14
Age (years) 24±1 28±1*
Body mass index (kg/m2) 23±1 24±1
Estrogen (pmol/l in women) 60±16 80±14
Sodium excretion (mmol/24 h) 230±31 270±31
Protein intake (gram/kg/day) 1.2±0.3 1.1±0.3
*Po0.05 vs GG subjects.
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Figure 1 | The effect of L-arginine on GFR in GG vs GT/TT subjects
(mean±s.e.m.). GFR¼glomerular filtration rate ml/min per
1.73 m2. *Po0.05 vs baseline GFR.
Table 2 | The hemodynamic response to L-arginine in men
and women by eNOS genotype (mean±s.e.m.)
Baseline 100 mg/kg 250 mg/kg 500 mg/kg
GG subjects
SBP 108±2 110±3 105±3 109±3
DBP 62±2 63±2 61±2 60±2
MAP 78±2 79±2 76±3 75±3
GFR 137±8 143±4 147±7 149±6*
ERPF 693±26 723±35* 787±40* 847±48*
FF 0.20±0.01 0.20±0.01 0.19±0.01 0.18±0.01*
RBF 1103±45 1151±59* 1234±65* 1300±73*
RVR 73±4 71±4 64±5* 60±4*
GT/TT subjects
SBP 116±3w 117±3w 114±4w 114±3
DBP 64±2 64±2 63±2 62±2
MAP 80±3 80±2 77±3 79±3
GFR 126±6w 120±5w 125±6w 131±7w
ERPF 686±49 668±43y 721±49y 754±48*,y
FF 0.18±0.01 0.19±0.01 0.18±0.01 0.18±0.01
RBF 1164±104 1109±80 1181±89 1220±87
RVR 75±8 78±6 64±7* 67±7*
ERPF, effective renal plasma flow in ml/min per 1.73 m2; FF, filtration fraction; GFR,
glomerular filtration rate in ml/min per 1.73 m2; MAP, mean arterial pressure
(mm Hg); RBF, renal blood flow in ml/min per 1.73 m2; RVR, renal vascular resistance
in mm Hg/l/min.
*Po0.05 vs within-group baseline value.
wPo0.05 for between-group differences.
yPo0.05 for the response vs GG subjects.
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Figure 2 | The effect of L-arginine on ERPF in GG vs GT/TT subjects
(mean±s.e.m.). ERPF¼ effective renal plasma flow in ml/min per
1.73 m2, *Po0.05 vs baseline value, yPo0.05 for the response vs
GT/TT group.
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association remains controversial.5 The aim of this study was
to determine if the G894T polymorphism influences the renal
hemodynamic response to eNOS enzymatic activation with
L-arginine in healthy men and women, thereby suggesting
that it is a functional polymorphism. Our major findings
were that in healthy subjects segregated into two groups on
the basis of the presence or absence of the T allele: (1) SBP
was significantly lower, and GFR significantly higher, in the
GG group compared to the GT/TT group at baseline; (2) The
renal hemodynamic response to the eNOS substrate,
L-arginine, was blunted in the GT/TT group compared to
those with the GG genotype; (3) The different hemodynamic
responses were not a function of eNOS expression levels or
circulating cGMP or RAS mediators, as these were similar
between the two groups.
NO is synthesized from the amino acid L-arginine by the
enzyme NOS.12 In the vascular endothelium, NO regulates
vasodilator tone13 by activating soluble guanylate cyclase and
increasing the production of cGMP.14 Under normal
physiologic conditions, eNOS, neuronal NOS and inducible
NOS are expressed in renal tissue and are directly involved in
the regulation of ERPF, GFR, and tubuloglomerular feed-
back.15,16 Intravenous administration of the substrate for
eNOS, L-arginine, results in a rise in ERPF and GFR in
animals17 and in normal humans.18–20 In addition to these
renal hemodynamic effects, previous work has suggested that
NO acts as a tonic vasodilator in the systemic circulation
thereby influencing arterial blood pressure regulation.13
Clinical studies have demonstrated that the G894T eNOS
gene polymorphism is associated with the development of
atherosclerosis and cardiovascular events, such as ischemic
heart disease, hypertension, carotid atherosclerosis, and
diabetic nephropathy.1,2,7–10 For example, Miyamoto et al.
demonstrated that the G894T eNOS polymorphism is
strongly linked with essential hypertension,10 and others
have demonstrated associations with endothelial dysfunction,
inflammation, and vasoconstriction.2,21 This may be due to a
variety of factors, including lower eNOS mRNA expression,22
diminished enzymatic activity,23 augmented vasoconstrictive
responses to Ang II and phenylephrine, and increased
generation of reactive oxygen species.11,24 Previous data have
not, however, been unanimous regarding the functional
nature of the G894T eNOS polymorphism.25 Whether this
polymorphism exerts an effect on cardiovascular or renal
hemodynamic physiology therefore remains unclear. Accord-
ingly, we assessed the impact of L-arginine, which is the
substrate for eNOS, on systemic and renal hemodynamic
function.
Our first major finding was that the SBP was lower in the
GG group compared to the GT/TT group at baseline and
during the 100 and 250 mg/kg doses of L-arginine. These
differences were no longer significantly different at the
highest dose of L-arginine. Our findings of a higher baseline
SBP and a lower GFR in a small sample of normal, young
adults may suggest a state of relative vasoconstriction, as
suggested in previous experimental and human stu-
dies.2,10,24,26 This vasoconstrictive phenotype may be due to
several factors. First, it may have been on the basis of
diminished baseline eNOS enzymatic activity, as suggested by
others.23 Second, the G894T eNOS polymorphism has been
associated with a lack of NO tissue bioavailability and an
increase in counterregulatory vasoconstrictive mechanisms,
such as the generation of reactive oxygen species through
interactions with asymmetric dimethyl arginine or inflam-
matory cytokines.26,27 This increase in the ratio of vasocon-
strictors to vasodilators may contribute to the increased risk
of hypertension10 and impaired endothelial function26 that
has been associated with the G894T eNOS polymorphism. In
the kidney, low NO bioactivity may have been associated
with a decline in GFR through a rise in preglomerular
resistance,16 or suppression of the ultrafiltration coefficient28
Regardless of the underlying physiologic explanation, our
study supports previous experimental and human findings,
which emphasize the concept that the T allele favors a state of
relative hypertension and vasoconstriction.
Our second major finding was that subjects with the T
allele exhibited a blunted renal vasodilatory response to the
L-arginine infusion compared to GG subjects. Previous
clinical studies have suggested that the G894T eNOS
polymorphism is associated with diminished activity of the
enzyme,22 leading to an augmented risk of developing
adverse clinical outcomes.1,8–10 Although controversial, some
Table 3 | Circulating RAS mediators and cGMP in response to
L-arginine in men and women analyzed by eNOS genotype
(mean±s.e.m.)
Baseline 100 mg/kg 250 mg/kg 500 mg/kg
GG
Aldosterone 289±62 79±12* 70±12* 82±16*
Angiotensin II 8.9±1.6 6.5±1.4* 4.8±0.9* 3.3±0.7*
cGMP 4.4±0.4 4.6±0.4 4.7±0.5 6.1±0.5*
PRA 1.2±0.3 0.7±0.2* 0.5±0.1* 0.6±0.2*
Renin 21±4 12±2* 12±3* 12±4*
GT/TT
Aldosterone 346±65 88±13* 86±17* 88±14*
Angiotensin II 12.1±2.2 7.3±1.0* 5.4±0.7* 4.9±1.2*
cGMP 4.2±0.3 4.9±0.5 5.1±0.6 6.3±0.7*
PRA 1.3±0.3 0.5±0.1* 0.9±0.4 0.7±0.2
Renin 20±4 12±2 13±2* 16±5*
cGMP, cyclic 30 ,50-guanosine monophosphate; PRA, plasma renin activity.
*Po0.05 vs within-group baseline.
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Figure 3 | eNOS expression in skin (mean±s.e.m.).
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investigators have attributed these outcomes to increased
arterial stiffness29 and decreased endothelial function in
experimental2 and human studies.26 In addition to dimin-
ished enzymatic activity, another mechanism that may have
contributed to the impaired hemodynamic responsiveness in
G894T polymorphism subjects is enhanced vasoconstrictor
sensitivity, which has been demonstrated previously.11,24
Based on the results of this study, blunted arterial
vasodilatory responsiveness to L-arginine may also contribute
to the vasoconstrictive hemodynamic phenotype that is
characteristic of humans with the G894T eNOS gene
polymorphism.
We expected that an augmented hemodynamic effect of
L-arginine in GG subjects would be associated with a greater
rise in cGMP if the phenomenon is based on increased eNOS
enzymatic activity. Our third observation was that eNOS
mRNA levels were similar in the two groups. In addition,
there was no difference in baseline circulating cGMP levels or
in the cGMP response to L-arginine. Even though circulating
cGMP levels were similar in the two groups, this may not
reflect intracellular NO bioavailability or the duration of its
activity, both of which may influence hemodynamic func-
tion.30,31 Moreover, although cGMP does correlate with NOS
activity, this association is not consistent, as described by
others.30–32 Taken together, these findings suggest that NO
bioavailability was augmented in GG compared the GT/TT
subjects, leading to exaggerated ERPF responsiveness.
From the vasoconstrictor perspective, similar to our
previous work,33 we observed that the graded L-arginine
infusion reduced circulating aldosterone and Ang II levels in
both groups of subjects. Interactions between Ang II and the
NO system have been observed in in vitro and in vivo
experiments.34,35 The suppressive effect of NO on Ang II may
be mediated through a negative feedback loop, whereby NO
abolishes Ang II-dependent vascular and mesangial contrac-
tion through the intracellular actions of cGMP.34–38 We also
observed that L-arginine suppressed circulating aldosterone
levels in both groups. This was perhaps not surprising,
because in animal models, NO activity is an important factor
that protects against the development of hypertension in the
presence of circulating mineralocorticoid and RAS hor-
mones.39,40 The augmented effect of L-arginine on renal
hemodynamic function in the GG group is unlikely to have
been on the basis of greater negative feedback inhibition on
the RAS because there was a greater reduction in circulating
RAS mediators in the GT/TT group.41 Our results suggest
that the hemodynamic impact of this polymorphism may be
compounded by a blunted vasodilatory responsiveness.
This study has several limitations. We attempted to
minimize the effect of the small sample size by utilizing
homogeneous study groups and by careful prestudy prepara-
tion with a focus on known factors such as sodium intake,
protein intake, and phase of the menstrual cycle, all of which
have been shown to influence the RAS and NO systems.42–47
In addition, we decreased variability by using a study design
that allowed each subject to act as his/her own control. The
small sample size in this study may have limited our ability to
detect between-group differences in certain parameters such
as circulating cGMP and RAS mediator levels. Finally,
although we were not able to examine the effect of T allele
homozygosity vs heterozygosity due to the small sample size,
the presence of at least one copy of the T allele is sufficient to
produce systemic11,21,24,26 and renal hemodynamic function
differences.11
In summary, the results from this physiologic study
suggest that the G894T eNOS gene polymorphism may be a
functional variant in healthy humans. The development of
hypertension and cardiovascular complications that has been
associated with the G894T eNOS gene polymorphism in
previous epidemiologic studies may be due to reduced NO
bioactivity, suggesting that this is an important area for
future clinical research.
MATERIALS AND METHODS
Subjects
Recruitment was in accordance with the policies of the Human
Subjects’ Review Committee of the University of Toronto. We
studied age-matched, otherwise healthy men and women, aged
18–40 years with normal body mass index, arterial blood pressure,
renal function, liver function, and electrocardiogram. Exclusion
criteria included a history of renal, cardiac, or lung disease or
current smoking or oral contraceptive use. No subjects ingested any
regular medications. In women, pregnancy was excluded before
enrolment with a negative serum b-HCG. All subjects were
interviewed and examined by a qualified internist.
Preparation
Each subject was studied on one occasion, after 7 days on a
controlled diet consisting of X150 mmol/day sodium and p1.5 g/
kg/day protein, as previously described.11,48–50 Compliance was
ascertained by measurement of 24-h urine sodium and urea
excretion on the seventh day. Data were analyzed if urine sodium
excretion was X150 mmol/day, and urea excretion was 3–6 mmol/
kg/day. Each subject presented to the Renal Physiology Laboratory
at the Toronto General Hospital at 0800 hours after an overnight
fast.
Experimental procedures
Each subject had an 18-gauge peripheral venous cannula inserted
into an antecubital vein for sampling, and a second cannula in the
contralateral arm for infusions. Each woman had a blood sample
collected for estradiol levels, to delineate phases of the menstrual
cycle. Women were studied during the low-estrogen, follicular phase
of the menstrual cycle to minimize the impact of estrogen on eNOS
activity.11 Data were not used if levels were inappropriate to the
follicular phase. No subjects were excluded based on those criteria.
Blood samples were collected for inulin blank and for baseline values
for aldosterone, Ang II, plasma renin activity (PRA), and renin. A
simultaneous blood sample for circulating cGMP was obtained as a
measure of NO bioactivity. Hemodynamic parameters (arterial
pressure, heart rate) were measured by an automated sphygmo-
manometer at 15 min intervals throughout the study. Renal
hemodynamic function was assessed using inulin and PAH clearance
techniques, as previously described in.11,48–50 After two clearance
periods had been completed, L-arginine (Clinalfa, Lau¨felfingen,
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Switzerland) was infused at 100, 250, and 500 mg/kg, with each
infusion period lasting 30 min.
Renal clearances were repeated after each infusion period, and
again after a 30 min recovery period. The inulin and PAH clearances,
corrected for body surface area, represented GFR and ERPF
respectively, expressed per 1.73 m2. Filtration fraction was deter-
mined by dividing the GFR by the ERPF. RBF was calculated by
dividing the ERPF by (1-hematocrit). RVR was derived by dividing
the mean arterial pressure by the RBF.
Biochemical assays
Ang II was measured by radioimmunoassay. Blood was collected
into prechilled tubes containing EDTA and angiotensinase inhibitor
(0.1 ml Bestatin Solution; Buhlmann Laboratories AG, Switzerland).
After centrifugation, plasma samples were stored at 70 1C until
analysis. On the day of analysis plasma samples were extracted on
phenylsilysilica columns. A competitive radioimmunoassay kit
supplied by Buhlmann Laboratories AG, Basel was used to measure
the extracted Ang II. Aldosterone was measured by radioimmu-
noassay, using the Coat-A-Count system. Angiotensinogen was
measured indirectly by converting endogenous angiotensinogen to
angiotensin I, then quantitating the amount of angiotensin I by
radioimmunoassay (PRA). Conversion was done by incubating the
plasma with an excess amount of exogenous renin at 37 1C for 18 h.
After measuring the produced angiotensin I, the endogenous
angiotensin I obtained before incubation was subtracted.51 Active
plasma renin was measured by two site immunoradiometric assay
where two monoclonal antibodies to human active renin are used.
One antibody was coupled to biotin whereas the second was
radiolabeled for detection. The sample containing active renin was
incubated simultaneously with both antibodies to form a complex.
The radioactivity of this complex was directly proportional to the
amount of immunoreactive renin present in the sample.52 Plasma
cGMP samples were deproteinized with ethanol. cGMP was
measured using the acetylation method with an assay kit purchased
from Cayman Chemical Company (Ann Arbor, MI, USA).
Determination of eNOS gene polymorphisms and skin biopsy
methodology
Genomic DNA was extracted from peripheral blood leukocytes as
described previously.24 The DNA was resuspended in TE buffer
(10 mmol/l Tris-HCl and 0.2 mmol/l sodium EDTA (pH 7.5)), and
the concentration then was determined by spectrophotometry. For
determining the eNOS genotype of each participant, 0.1 mg of
genomic DNA was amplified by PCR. The 20-ml reaction mixture
contained 2 ml of 10 KCl-containing PCR buffer (Qiagen,
Valencia, CA, USA); 0.8ml of 25 mM MgCl2 solution; 1 ml each of
the 10-mM sense and antisense primers; 3.2 ml of 1.25 mM
deoxynucleotide triphosphates, specifically deoxyadenosine tripho-
sphate, guanosine triphosphate, cytosine triphosphate, and thymi-
dine triphosphate; and 2.5 U of TaqDNA polymerase. A total of 34
cycles of PCR were performed: 30 s at 94 1C, 30 s at 61 1C, and 30 s at
71 1C. The primer sequences were as follows: 50-TCCCTGAGGA
GGGCATGAGGCT-30 and 50-TGAGGGTCACACAGGTTCCT-30.25
This PCR amplification yielded a 457-bp product from which
unused deoxynucleotide triphosphates and primers were separated
using a commercial filtration system (Microcon-PCR Filter Units;
Millipore, Bedford, MA, USA). The purified PCR products then
were reconstituted in 20 ml of distilled water and subjected to
overnight incubation at 37 1C with 7.5 U of the restriction
endonuclease BanII (New England Biolabs, Beverly, MA, USA).
The 894G allele of the eNOS gene contains a recognition site for
BanII such that digestion of the 457 bp amplicon with the
endonuclease yielded two fragments of 320 and 137 bp each. The
change to T at the 894 position disrupts the recognition sequence
such that the original 457-bp amplicon remains unaltered after
incubation with BanII. The digestion products were separated using
2% agarose gel electrophoresis and stained in ethidium bromide.
To obtain eNOS mRNA, a skin biopsy was performed in each
subject at baseline under sterile conditions after subcutaneous
infusion of local anesthetic. Biopsy samples were stored in liquid
nitrogen at 70 1C before processing. eNOS mRNA levels were
assessed by a PCR protocol using the One-Step RT–PCR kit (Applied
Biosystems, Foster City, CA, USA), as described in previous
studies.33,47,53
Analysis
The data were analyzed on the basis of the presence or absence of the
T allele, as reported in previous human physiologic studies.11,21,24,26
Results are presented as mean±s.e.m. A P-value p0.05 was
considered statistically significant. Between-group comparisons of
all parameters at baseline were made using parametric methods
(unpaired t-test). Within-subject and between-group differences in
all hemodynamic and biochemical responses to L-arginine were
determined by repeated measures analysis of variance (ANOVA). All
statistical analyses were performed using the statistical package SPSS
(SPSS for graduate students, Version 14.0).
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